Clinical Policy: Fecal Microbiota, Live-jslm (Rebyota)
Reference Number: LA.PHAR.613
Effective Date:
Last Review Date: 05.01.23
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

**Please note: This policy is for medical benefit**

**Description**
Fecal microbiota, live-jslm (Rebyota™) is a fecal microbiota suspension manufactured from human fecal matter sourced from qualified donors.

**FDA Approved Indication(s)**
Rebyota is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

Limitation(s) of use: Rebyota is not indicated for treatment of CDI.

**Policy/Criteria**
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections® that Rebyota is medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Prevention of Clostridioides difficile Infection (must meet all):
      1. Diagnosis of CDI confirmed by documentation of positive Clostridioides difficile test;
      2. Age ≥ 18 years;
      3. Member has recurrent CDI as evidenced by one of the following (a or b):
         a. At least 2 episodes of CDI recurrence after a primary episode (i.e., total 3 episodes);
         b. At least 2 episodes of severe CDI resulting in hospitalization within the last year;
      4. Member has received at least 10 consecutive days of antibiotic therapy for the current CDI (e.g., metronidazole, vancomycin, fidaxomicin);
      5. The current CDI is controlled (< 3 unformed/loose stools/day for 2 consecutive days [i.e., diarrhea, or Bristol Stool Scale type 6-7]);
      6. Member has not previously received Rebyota treatment or prior fecal microbiota transplant;
      7. Dose does not exceed a single dose of 150 mL.
   Approval duration: 3 months (1 dose only)

   B. Other diagnoses/indications (must meet 1 or 2):
CLINICAL POLICY
Fecal Microbiota, Live-ism

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

II. Continued Therapy
   A. Prevention of *Clostridioides difficile* Infection
      1. Re-authorization is not permitted as the efficacy of repeat courses of Rebyota has not been sufficiently established (see Appendix D).
      Approval duration: Not applicable

   B. Other diagnoses/indications (must meet 1 or 2):
      1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
      2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 2 above does not apply, refer to the off-label use policy for the relevant line of business: LA.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:
   A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – LA.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information
   Appendix A: Abbreviation/Acronym Key
   CDI: *Clostridioides difficile* infection
   FDA: Food and Drug Administration
   IDSA: Infectious Diseases Society of America

   Appendix B: Therapeutic Alternatives
   This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dificid® (fidaxomicin)</td>
<td>200 mg PO BID for 10 days; for recurrences, may use alternative regimen of 200 mg PO BID for 5 days, followed by QOD for 20 days</td>
<td>See regimen</td>
</tr>
<tr>
<td>metronidazole</td>
<td>500 mg PO TID for 10-14 days</td>
<td>See regimen</td>
</tr>
</tbody>
</table>
**Clinical Policy**

**Fecal Microbiota, Live-jslm**

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>vancomycin</td>
<td>125 mg PO QID for 10 days; for recurrences, may use a tapered and pulsed regimen</td>
<td>See regimen</td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as *Brand name®* (generic) when the drug is available by brand name only and *generic (Brand name®)* when the drug is available by both brand and generic.

**Appendix C: Contraindications/Boxed Warnings**

- Contraindication(s): severe allergic reactions (e.g., anaphylaxis) to any component of Rebyota
- Boxed warning(s): none reported

**Appendix D: General Information**

- Both the Infectious Diseases Society of America (IDSA) and the American College of Gastroenterology recommend fecal microbiota transplantation for patients experiencing their second or further recurrence of CDI.
- Approximately 35% of CDI patients experience recurrence after the initial treatment and resolution of diarrhea. Of those who have a primary recurrence, 40% will have another CDI episode, and after 2 recurrences, the chance of an additional episode increases to as high as 65%.
- Per the 2017 IDSA Clinical Practice Guidelines for CDI:
  - An incident case is one with a new primary symptom onset (i.e., in the previous 8 weeks, there was not an episode of positive symptoms with positive *Clostridioides difficile* result) and positive *Clostridioides difficile* assay result.
  - A recurrent infection is an episode of symptom onset with a positive assay result following an episode with positive assay result in the previous 2-8 weeks.
- Per the 2021 IDSA Focused Update for CDI in Adults:
  - Fidaxomicin is the preferred first-line treatment for patients with recurrent CDI episodes.
  - Vancomycin (in a tapered and pulsed regimen or as a standard course) is an alternative treatment for CDI recurrence.
  - Bezlotoxumab (Zinplava®) is an adjunctive treatment that may be used in addition to standard of care antibiotics for patients with a recurrent CDI episode within the last 6 months.
  - Prior to fecal microbiota transplantation, appropriate antibiotic treatments for at least 2 recurrences (i.e., 3 CDI episodes) should be tried.
  - Examples of treatment regimens for recurrence:
    - Vancomycin 125 mg PO QID for 10 days (may be followed by rifaximin 400 mg PO TID for 20 days)
    - Tapered and pulsed regimens of vancomycin (e.g., vancomycin PO 125 mg QID for 10 to 14 days, then BID for 1 week, then QD for 1 week, then every 2 or 3 days for 2 to 8 weeks)
    - Fidaxomicin 200 mg PO BID for 10 days
CLINICAL POLICY

Fecal Microbiota, Live-jslm

- Fidaxomicin 200 mg PO BID for 5 days followed by once every other day for 20 days
- Fecal microbiota transplantation
- Bezlotoxumab 10 mg/kg IV once during administration of standard of care antibiotics

- The Bristol Stool Scale is a tool to define stool types. Types 1-2 indicate constipated stool. Types 6-7 indicate diarrheal stool.
  - Type 1: separate hard lumps, like nuts
  - Type 2: sausage-shaped but lumpy
  - Type 3: like a sausage but with cracks on its surface
  - Type 4: like a sausage or snake, smooth and soft
  - Type 5: soft blobs with clear-cut edges (passed easily)
  - Type 6: fluffy pieces with ragged edges, a mushy stool
  - Type 7: watery, no solid pieces (entirely liquid)

- Repeat courses: In the event of treatment failure (i.e., CDI diarrhea) within the first 8 weeks of blinded treatment, participants in the PUNCH CD3 phase 3 study were allowed to receive an open-label second treatment course of Rebyota. However, only 41/180 (22.8%) patients who received an initial course of Rebyota received this second course, and of those 41, only 22 (53.8% of the patients who received a second treatment course; 12.2% of the original population) ultimately achieved treatment success. Given that this was an open-label treatment and included a relatively small sample, this is considered insufficient data to support a second treatment course at this time. In addition, the FDA label indicates only 1 dose should be administered and does not address repeat courses.

V. Dosage and Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dosing Regimen</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevention of CDI</td>
<td>Administer a single dose of 150 mL rectally of Rebyota 24 to 72 hours after the last dose of antibiotics for CDI</td>
<td>See regimen</td>
</tr>
</tbody>
</table>

VI. Product Availability

Suspension (a single dose is 150 mL)

VII. References


Reviews, Revisions, and Approvals

<table>
<thead>
<tr>
<th>Date</th>
<th>LDH Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created</td>
<td>05.01.23</td>
</tr>
</tbody>
</table>

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal
CLINICAL POLICY
Fecal Microbiota, Live-jslm

and regulatory requirements relating to provider notification. If there is a discrepancy between
the effective date of this clinical policy and any applicable legal or regulatory requirement, the
requirements of law and regulation shall govern. LHCC retains the right to change, amend or
withdraw this clinical policy, and additional clinical policies may be developed and adopted as
needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is
not intended to dictate to providers how to practice medicine. Providers are expected to exercise
professional medical judgment in providing the most appropriate care and are solely responsible
for the medical advice and treatment of members. This clinical policy is not intended to
recommend treatment for members. Members should consult with their treating physician in
connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent
judgment and over whom LHCC has no control or right of control. Providers are not agents or
employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this
clinical policy or any information contained herein are strictly prohibited. Providers, members,
and their representatives are bound to the terms and conditions expressed herein through the
terms of their contracts. Where no such contract exists, providers, members and their
representatives agree to be bound by such terms and conditions by providing services to
members and/or submitting claims for payment for such services.

©2023 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively
owned by Louisiana Healthcare Connections and are protected by United States copyright law
and international copyright law. No part of this publication may be reproduced, copied,
modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any
means, or otherwise published without the prior written permission of Louisiana Healthcare
Connections. You may not alter or remove any trademark, copyright or other notice contained
herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by
Louisiana Healthcare Connections.